TerrAscend Faces Michigan Receivership and $10.7M DOJ Tax Claim Amidst Mixed Q1 Results and Cannabis Rescheduling

summarizeSummary

TerrAscend reported mixed Q1 2026 results with revenue growth but declining Adjusted EBITDA, while facing a Michigan receivership and a $10.7 million tax refund repayment claim from the DOJ. The company is also assessing the uncertain impact of medical cannabis rescheduling.

check_boxKey Events

• Michigan Operations Enter Receivership

  On May 5, 2026, the company's primary lender filed for receivership in Michigan, leading to the appointment of a receiver over the Michigan entities on May 6, 2026, to liquidate assets and resolve liabilities. This follows the company's June 2025 plan to exit the Michigan market.

• DOJ Seeks $10.7M Tax Refund Repayment

  The U.S. Department of Justice is seeking repayment of approximately $9.533 million in a federal income tax refund, plus an estimated $1.172 million in interest, for the 2020 tax year. The company intends to vigorously defend its position.

• Medical Cannabis Rescheduled to Schedule III

  Effective April 28, 2026, medical cannabis was reclassified from Schedule I to Schedule III under the Controlled Substances Act. This could lead to Section 280E tax relief for medical licensees, but the ultimate financial impact on TerrAscend is still being evaluated.

• Mixed Q1 2026 Financial Performance

  Net revenue increased by 2% year-over-year to $65.5 million, driven by retail growth. However, gross profit margin decreased to 52.8% from 53.9%, and Adjusted EBITDA from continuing operations declined to $17.4 million from $18.1 million in the prior year period. Net loss improved to $(8.0) million from $(12.3) million, but free cash flow decreased to $7.8 million from $8.8 million.

auto_awesomeAnalysis

TerrAscend Corp. is navigating significant legal and operational challenges. The appointment of a receiver for its Michigan entities signals a distressed exit from that market, which, while stated not to impact continuing operations, represents a material restructuring. Concurrently, the U.S. Department of Justice is seeking repayment of a substantial $10.7 million federal income tax refund, posing a direct financial risk equivalent to approximately 3.8% of the company's market capitalization. These events introduce considerable uncertainty and risk. While the reclassification of medical cannabis to Schedule III by the Attorney General is a potentially positive industry development, its specific financial impact on TerrAscend, particularly regarding retrospective 280E tax relief, remains uncertain and under evaluation. Investors should monitor the outcome of the Michigan receivership, the DOJ tax claim, and the evolving regulatory landscape for cannabis rescheduling.